DNAlite Therapeutics, Inc. is an early-stage preclinical biotechnology company focused on developing innovative gene therapies. The company leverages proprietary vector technology to create oral and non-immunogenic medicines aimed at overcoming the limitations of current biological treatments. DNAlite's primary objective is to modify the gastrointestinal (GI) tract to restore its functionality in patients with genetic diseases or compromised mucosa. By targeting GI cells with DNA and RNA, the company aims to address both intestinal and systemic diseases. DNAlite operates in the biotechnology sector, serving patients with genetic and GI-related conditions. Its business model revolves around the research and development of novel gene therapies, with revenue generation expected from licensing agreements, partnerships, and eventual commercialization of its therapeutic products.

Keywords: gene therapy, biotechnology, gastrointestinal, non-immunogenic, vector technology, genetic diseases, preclinical, oral administration, systemic diseases, innovative medicines.